Travere Therapeutics, Inc. TVTX

US Biotechnology

$50.75 ▼ -1.70% ($-0.88)

Open $51.69

Prev Close $51.63

Day Range $50.72 – $51.70

52W Range $22.59 – $68.73

Market Cap $4.76B

Beta 1.09

EPS (TTM) $-1.30

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2003-07-23
Shares Out.	94,260,000
Website	travere.com/ ↗
Phone	18889697879
Employees	497
Revenue	$224.6M
Gross Profit	$221.7M
Net Income	-$52.3M
Free Cash Flow	$63.8M
Total Assets	$848.2M
Total Liabilities	$825.6M
Equity	$22.6M

About Travere Therapeutics, Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

Travere Therapeutics, Inc. is a publicly traded company under the ticker symbol TVTX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.